Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

or LEMS in the U.S. by early 2011.  If successful, NDA submission is expected in the first half of 2012, followed by approval by the end of 2012.
  • GALNS for MPS IVA: BioMarin expects to initiate a 24-week pivotal Phase III study with six-minute walk distance as the primary endpoint early in the first quarter of 2011.
  • Kuvan outcomes study/ Hand-Held Blood Phe Monitor: PKU-016, a randomized, placebo-controlled, 13-week Kuvan outcomes study is ongoing.  Endpoints include clinically validated measures of neuropsychiatric symptoms and if successful, may enable a label amendment.  Several other programs are underway to expand and protect the market and to improve the ability of healthcare providers and patients to better manage PKU.  These programs include a state-of-the-art handheld device to measure blood Phe levels in PKU patients. Regulatory approval and commercial availability of the handheld blood Phe monitor are expected in late 2011.

  • Mid-Stage Programs

  • PEG-PAL for PKU: The ongoing Phase II clinical trial is an open-label, multi-center study conducted in a series of dose-escalating cohorts.  The primary treatment period of eight weekly injections at a fixed dose is followed by dose and frequency optimization and an extension period.  All top-line results for the Phase II study, including a study comparing daily and weekly dosing and a formulation study are expected in mid-2011.  The company expects to initiate a Phase III trial in the fourth quarter of 2011 or the first quarter of 2012.

  • Preclinical Programs

  • BMN-673 (PARP inhibitor):  The company expects to file an IND for BMN-673 by the end of 2010 and initiate a Phase 1b trial in the first quarter of 2011.  BioMarin believes that, based upon internal preclinical experiments, BMN-673 may be ultimately superior to other compounds currently in clinical development.
  • '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin to Host a Research and Development Day on October 19th
    2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    3. BioMarin to Present at the UBS Global Life Sciences Conference
    4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
    5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
    6. BioMarin Acquires ZyStor Therapeutics, Inc.
    7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
    8. BioMarin to Acquire LEAD Therapeutics
    9. BioMarin to Present at the Credit Suisse Healthcare Conference
    10. BioMarin Announces Third Quarter 2009 Financial Results
    11. BioMarin to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... Oct. 1, 2014 Trovagene, Inc., (NASDAQ: ... today that Eli Diamond , MD, Assistant ... (MSK), presented clinical data from an ongoing study ... platform for the determination of oncogene mutational status ... The results were presented to both treating physicians ...
    (Date:10/1/2014)... , Oct. 1, 2014   Cypher Genomics, Inc., ... of J. Patrick Ravenel as chief technology ... software and systems experience and a proven track record ... "Patrick has been recognized as a ... systems and is known industry-wide for delivering innovative products ...
    (Date:10/1/2014)... 1, 2014 Quantum Materials Corp (OTCQB:QTMM) ... of photoactive quantum dots for use in ... numerous advantages for solar power generation, the high ... quantum dots with which to develop thin film ... commercial utilization and acceptance. The company is also ...
    Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
    ... growing appetite for health and wellness devices, and this represents ... been tapped, according to a study from IBM (NYSE: ... wellness device innovations of the future, which have the potential ... healthcare provider over the next five years. (Photo: ...
    ... 2011 Providers of durable medical equipment and services (DME) ... repeal Medicare,s controversial "competitive" bidding for homecare, which cuts quality ... The program is opposed by the ... advocacy groups such as the ALS Association and ...
    Cached Medicine Technology:IBM Study Identifies New Generation of Connected Health Devices 2IBM Study Identifies New Generation of Connected Health Devices 3IBM Study Identifies New Generation of Connected Health Devices 4IBM Study Identifies New Generation of Connected Health Devices 5At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 2At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 3At-Home Care Businesses Urge President Obama to Repeal Medicare Program that Cuts Access to Homecare 4
    (Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
    (Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
    (Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 ... NoteSwift is the bridge between the EHR and Dragon ... clinical information at the point of care. NoteSwift reduces ... by more than half – and virtually eliminates mouse ... state impedes EHR use according to the June 12, ...
    (Date:10/1/2014)... 01, 2014 Nordic Naturals is ... very special cause. The campaign—“Buy One Bottle. Help ... for Veterans, a nonprofit organization that helps rebuild ... shelter dogs that would otherwise face euthanasia. From ... will support monthly donations of Nordic Naturals omega-3s ...
    (Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
    Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
    ... hope to detect the disease while it is still ... scientists say they have found small molecules in the ... could have diagnostic implications in the future. , Levels ... suffering from pancreatic cancer, the fourth-leading cancer killer in ...
    ... harsh skin toxicity associated with a widely used cancer drug, ... Cancer Biology and Therapy by researchers from City of ... (Erbitux) is a monoclonal antibody that binds to and inhibits ... to treat colorectal cancer and head and neck cancer. Although ...
    ... combined with a defibrillator (CRT-D) implanted had a 34 ... failure when compared to patients receiving only an implanted ... online today in the New England Journal of ... of Cardiology Congress (ESC) in Barcelona, Spain. The overall ...
    ... is available in French . , ... serious autoimmune disorders which cause muscular inflammation are at ... of Montreal researchers. Dr. Christian A. Pineau and his ... Health Centre (RI-MUHC) have linked muscular inflammation to increased ...
    ... , , , , ... in grants for four Northwest nonprofits: HealthMatters of Central Oregon ... Northwest Organization of Nurse Executives . The grants all ... increase access to care. , , "At The Regence ...
    ... , PITTSBURGH, Sept. 1 On Friday, September 18, ... former president of the renowned public relations agency Porter Novelli, former ... native William (Bill) D. Novelli. Enjoy lunch and a presentation ... to accomplish this, and what it means for seniors in the ...
    Cached Medicine News:Health News:Blood Test May Spot Pancreatic Cancer Early 2Health News:Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs 2Health News:Stuy in NEJM: New therapy prevents heart failure 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2Health News:Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits 2
    Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
    Used in the peritoneal cavity to remove large volumes of thick exudate....
    Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
    Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
    Medicine Products: